Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Regular financial reviews help you stay aligned with your goals and adjust to changing circumstances. Learn their importance for effective planning.
24,086 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
A concentrated bet from a top consumer-focused fund puts Chime in the spotlight. Discover what the $227 million posit...
The retirement safety net could face headwinds as projected funding gaps loom. This guide explains what could happen,...
In the past 30 days, ethereum lost month. here's a look at what spurred the decline and how investors can navigate po...
Markets can overreact to short-term costs even when the long-term AI story is intact. This article outlines one overs...
A federal lawsuit claims Meta’s Ray-Ban AI glasses expose user footage to human reviewers overseas, challenging the c...
When a major tech name drops, many investors feel the urge to retreat. Yet history shows that this tech stock down mo...
Defi’s hack vectors fading has cooled old-style theft, but a multi-chain vulnerability tied to replicated code across...
Meta's plan to price AR glasses at $300 could be a turning point for investors. This article breaks down the potentia...
A late-July meeting to craft an ethics clause for the President’s crypto holdings stalled, keeping Clarity Act negoti...
A stock that looks dirt cheap can spark big dreams of rapid gains. Before you chase an 83% rally, learn a practical f...
When Gartner stock sagged today, traders weighed a price-target cut and the broader tech sentiment. This article brea...